Reducing morbidity and mortality in patients with CKD and T2DM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Disease-modifying effects of finerenone in CKM syndrome
Disease-modifying effects of finerenone in CKM syndrome
ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
- Muthiah Vaduganathan, MD
Causal relationship between elevated Lp(a) levels and CKD risk
Causal relationship between elevated Lp(a) levels and CKD risk
EAS 2024
Causal relationship between elevated Lp(a) levels and CKD risk
- Anne Langsted, MD, PhD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD